1. Scrip
  2. >>Business
  3. >>Strategy

Organon Is Ready To Launch And Makes The Case To Investors

Established Products Will Account For The Majority Of Revenues

 
• By Jessica Merrill

Merck & Co. plans to spin off Organon in June as a diversified health care company focused on women's health, biosimilars and established products.

hot air balloon
Organon will launch as a new public company in June • Source: Alamy

Organon is poised to become a new independent company that will begin trading on the New York Stock Exchange on 3 June under the ticker OGN. The company, with a three-pronged business portfolio including women's health, biosimilars and established products, will generate $6.1bn-$6.4bn in 2021 on a pro forma basis, according to management’s forecast.

The company's new leadership team made the business case for Organon to Wall Street during an investor overview on 3 May, but it remains to be seen how investors will react to a business heavily weighted to mature brands and seemingly made up of disparate parts

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.